TRexBio raises $117 million in IPO as Retension secures $45 million Nasdaq debut for hypertension therapy

TRexBio completed its initial public offering on Thursday, pricing the shares at a level that generated about $116.7 million in gross proceeds. The funding will support the company’s development of regulatory T cell (Treg) therapies.

At the same time, fellow biotech Retension made its Nasdaq debut, raising roughly $45 million to advance its hypertension program. Both offerings underscore continued investor enthusiasm for biotech ventures.

Industry observers note that the strong demand is helped by partnerships with major players such as Eli Lilly and the involvement of Nobel‑prize‑winning scientific research, suggesting confidence in the pipeline of these companies.